The Impact of Charlson Comorbidity Index on Mortality From SARS-CoV-2 Virus Infection

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2022 Jan 3

PMID 34976530

Citations 4

Authors

Jawad Ahmed

Camilo Andres Avendano Capriles

Natalia M Avendano Capriles

Shivani M Mehta

Nattaliea Khan

Sheharyar Tariq

Ramsha Abbas

Sohaib Tousif

Khizer Shamim

Affiliations

Soon will be listed here.

Abstract

Introduction: Charlson Comorbidity Index (CCI) is a simple, validated, and readily acceptable method of determining the risk of mortality from comorbid disease. It has been used as a predictor of long-term survival and prognosis. The aim of this study is to determine the impact of CCI score on mortality in COVID-19 hospitalized patients and test the efficacy of the CoLACD score (COVID-19 lymphocyte ratio, age, CCI score, dyspnoea) in predicting mortality among hospitalized COVID-19 patients.

Methodology: It was a retrospective cohort, and the data of this study were gathered from two tertiary hospitals of Karachi, including Liaquat National Hospital and Ziauddin Hospital. Data of patients hospitalized in any of these tertiary care hospitals and diagnosed with confirmed COVID-19 infection were used in the study from January 15, 2021, to April 30, 2021.

Results: The mean age of participants was 53.22 (±14.21) years. The majority of participants were males (74.91%). Predictors of mortality include CCI score, age of participants, D-dimer, smoking status, and shortness of breath. The sensitivity of this CoLACD score was 80.23%, and specificity was 50.23% (diagnostic accuracy is 60.45%). The negative predictive value (NPV) of this test was 39.44%, and the positive predictive value (PPV) was 83.01%.

Conclusion: Our study showed that CCI can be used in a clinical setting to achieve a prediction of mortality in COVID-19 patients.

Citing Articles

Investigating the role of obstructive pulmonary diseases and eosinophil count at admission on all-cause mortality in SARS-CoV-2 patients : A single center registry-based retrospective cohort study.

Salai G, Vrazic H, Kovacevic I, Malnar Janes L, Marasovic I, Ranilovic D Wien Klin Wochenschr. 2023; 135(9-10):235-243.

PMID: 37093279 PMC: 10124688. DOI: 10.1007/s00508-023-02180-w.

Care Needs of Highly Complex Chronic Patients in the Canary Islands: An Observational Study.

Rodriguez-Alvaro M, Fernandez-Gutierrez D, Cabeza-Mora A, Barrios-Torres R, Nursing Methodology Group General Directorate Of Health Care Programs Of The Canary Islands Health Service Primary Care , Brito-Brito P Nurs Rep. 2023; 13(1):1-16.

PMID: 36648975 PMC: 9844377. DOI: 10.3390/nursrep13010001.

Charlson comorbidity index, neutrophil-to-lymphocyte ratio and undertreatment with renin-angiotensin-aldosterone system inhibitors predict in-hospital mortality of hospitalized COVID-19 patients during the omicron dominant period.

Sonaglioni A, Lombardo M, Albini A, Noonan D, Re M, Cassandro R Front Immunol. 2022; 13:958418.

PMID: 36090992 PMC: 9453812. DOI: 10.3389/fimmu.2022.958418.

Ability of IMPROVE and IMPROVE-DD scores to predict outcomes in patients with severe COVID-19: a prospective observational study.

Adolf Helmy M, Magdy Milad L, Hasanin A, Elbasha Y, ElSabbagh H, Elmarzouky M Sci Rep. 2022; 12(1):13323.

PMID: 35922436 PMC: 9349222. DOI: 10.1038/s41598-022-17466-8.

References

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J . Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 323(11):1061-1069. PMC: 7042881. DOI: 10.1001/jama.2020.1585. View

Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y . Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020; 146(1):110-118. PMC: 7152876. DOI: 10.1016/j.jaci.2020.04.006. View

Charlson M, Pompei P, Ales K, MacKenzie C . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-83. DOI: 10.1016/0021-9681(87)90171-8. View

Gong J, Ou J, Qiu X, Jie Y, Chen Y, Yuan L . A Tool for Early Prediction of Severe Coronavirus Disease 2019 (COVID-19): A Multicenter Study Using the Risk Nomogram in Wuhan and Guangdong, China. Clin Infect Dis. 2020; 71(15):833-840. PMC: 7184338. DOI: 10.1093/cid/ciaa443. View

Marroquin B, Vine V, Morgan R . Mental health during the COVID-19 pandemic: Effects of stay-at-home policies, social distancing behavior, and social resources. Psychiatry Res. 2020; 293:113419. PMC: 7439968. DOI: 10.1016/j.psychres.2020.113419. View

Carter J, Sketris I, Tamim H, Levy A, Langley J . Determining proton pump inhibitor prescription dispensing patterns and adherence to STOPP criteria for Nova Scotia Seniors Pharmacare Program beneficiaries. J Popul Ther Clin Pharmacol. 2020; 26(4):e37-e53. DOI: 10.15586/jptcp.v26i4.053. View

Huang I, Pranata R, Lim M, Oehadian A, Alisjahbana B . C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis. Ther Adv Respir Dis. 2020; 14:1753466620937175. PMC: 7336828. DOI: 10.1177/1753466620937175. View

Du R, Liang L, Yang C, Wang W, Cao T, Li M . Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Respir J. 2020; 55(5). PMC: 7144257. DOI: 10.1183/13993003.00524-2020. View

Yonas E, Alwi I, Pranata R, Huang I, Lim M, Gutierrez E . Effect of heart failure on the outcome of COVID-19 - A meta analysis and systematic review. Am J Emerg Med. 2020; 46:204-211. PMC: 7347316. DOI: 10.1016/j.ajem.2020.07.009. View

10.

Myrstad M, Ihle-Hansen H, Tveita A, Andersen E, Nygard S, Tveit A . National Early Warning Score 2 (NEWS2) on admission predicts severe disease and in-hospital mortality from Covid-19 - a prospective cohort study. Scand J Trauma Resusc Emerg Med. 2020; 28(1):66. PMC: 7356106. DOI: 10.1186/s13049-020-00764-3. View

11.

Imam Z, Odish F, Gill I, OConnor D, Armstrong J, Vanood A . Older age and comorbidity are independent mortality predictors in a large cohort of 1305 COVID-19 patients in Michigan, United States. J Intern Med. 2020; 288(4):469-476. PMC: 7300881. DOI: 10.1111/joim.13119. View

12.

Ji D, Zhang D, Xu J, Chen Z, Yang T, Zhao P . Prediction for Progression Risk in Patients With COVID-19 Pneumonia: The CALL Score. Clin Infect Dis. 2020; 71(6):1393-1399. PMC: 7184473. DOI: 10.1093/cid/ciaa414. View

13.

Varol Y, Hakoglu B, Cirak A, Polat G, Komurcuoglu B, Akkol B . The impact of charlson comorbidity index on mortality from SARS-CoV-2 virus infection and A novel COVID-19 mortality index: CoLACD. Int J Clin Pract. 2020; 75(4):e13858. PMC: 7744887. DOI: 10.1111/ijcp.13858. View

14.

Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y . Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395(10223):507-513. PMC: 7135076. DOI: 10.1016/S0140-6736(20)30211-7. View

15.

Christensen D, Strange J, Gislason G, Torp-Pedersen C, Gerds T, Fosbol E . Charlson Comorbidity Index Score and Risk of Severe Outcome and Death in Danish COVID-19 Patients. J Gen Intern Med. 2020; 35(9):2801-2803. PMC: 7314426. DOI: 10.1007/s11606-020-05991-z. View